Source: Fierce Pharma
Moderna is on a steady march to market with its mRNA-based COVID-19 vaccine, and the company is snapping up manufacturing capacity along the way. After inking one fill-finish deal with major CDMO Catalent last month, Moderna has now put its name to a second pact.
Moderna signed a deal with Spain’s Laboratorios Farmacéuticos Rovi for fill-finish duties on “hundreds of millions” of the Massachusetts-based vaccine maker’s mRNA COVID-19 shot candidate, the partners said Thursday.
Rovi will tackle the finishing work for Moderna’s vaccine at its Madrid facility after purchasing a new production line and equipment for compounding, filling, automatic visual inspection and labeling, according to a joint release.
Rovi expects to start the work in early 2021 and will hire additional staff to take on the increased manufacturing load. The partners did not disclose financial terms for the deal.
Moderna’s newest fill-finish pact with Rovi comes as the biotech looks to secure large-scale manufacturing for its shot, which it hopes to take into phase 3 human testing this month.
In late June, Catalent teamed with Moderna to handle fill-finish duties for up to 100 million doses of Moderna’s shot at the CDMO’s Bloomington, Indiana facility.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE